These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30375745)

  • 1. Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Néel A; Bucchia M; Néel M; Tilly G; Caristan A; Yap M; Rimbert M; Bruneau S; Cadoux M; Agard C; Hourmant M; Godmer P; Brouard S; Bressollette C; Hamidou M; Josien R; Fakhouri F; Degauque N
    Arthritis Rheumatol; 2019 Apr; 71(4):641-650. PubMed ID: 30375745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
    van Dam LS; Oskam JM; Kamerling SWA; Arends EJ; Bredewold OW; Berkowska MA; van Dongen JJM; Rabelink TJ; van Kooten C; Teng YKO
    Front Immunol; 2020; 11():566732. PubMed ID: 33384685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
    Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.
    Chocova Z; Hruskova Z; Mareckova H; Svobodova B; Duskova D; Bednarova V; Jancova E; Rysava R; Tesar V
    Clin Rheumatol; 2015 Jan; 34(1):107-15. PubMed ID: 25388644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population.
    Free ME; Bunch DO; McGregor JA; Jones BE; Berg EA; Hogan SL; Hu Y; Preston GA; Jennette JC; Falk RJ; Su MA
    Arthritis Rheum; 2013 Jul; 65(7):1922-33. PubMed ID: 23553415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
    Kallenberg CG
    Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
    Kallenberg CG; Hauser T
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
    Unizony S; Lim N; Phippard DJ; Carey VJ; Miloslavsky EM; Tchao NK; Iklé D; Asare AL; Merkel PA; Monach PA; Seo P; St Clair EW; Langford CA; Spiera R; Hoffman GS; Kallenberg CG; Specks U; Stone JH
    Arthritis Rheumatol; 2015 Feb; 67(2):535-44. PubMed ID: 25332071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease.
    Venhoff N; Niessen L; Kreuzaler M; Rolink AG; Hässler F; Rizzi M; Voll RE; Thiel J
    Autoimmunity; 2014 Sep; 47(6):401-8. PubMed ID: 24798501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory B cells in ANCA-associated vasculitis.
    Wilde B; Thewissen M; Damoiseaux J; Knippenberg S; Hilhorst M; van Paassen P; Witzke O; Cohen Tervaert JW
    Ann Rheum Dis; 2013 Aug; 72(8):1416-9. PubMed ID: 23666929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell-targeted therapy in systemic vasculitis.
    Lally L; Spiera R
    Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis.
    Todd SK; Pepper RJ; Draibe J; Tanna A; Pusey CD; Mauri C; Salama AD
    Rheumatology (Oxford); 2014 Sep; 53(9):1693-703. PubMed ID: 24729396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F; Jayne DR
    Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides.
    Thiel J; Salzer U; Hässler F; Effelsberg NM; Hentze C; Sic H; Bartsch M; Miehle N; Peter HH; Warnatz K; Schlesier M; Voll RE; Venhoff N
    Autoimmunity; 2013 Nov; 46(7):429-38. PubMed ID: 23742274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
    Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
    Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered circulating CCR6
    Liao Z; Tang J; Luo L; Deng S; Luo L; Wang F; Yuan X; Hu X; Feng J; Li X
    Arthritis Res Ther; 2021 Jul; 23(1):194. PubMed ID: 34289887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
    Venhoff N; Effelsberg NM; Salzer U; Warnatz K; Peter HH; Lebrecht D; Schlesier M; Voll RE; Thiel J
    PLoS One; 2012; 7(5):e37626. PubMed ID: 22629432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.